
|Videos|November 15, 2020
AAO 2020: Alimera highlights NEW DAY Study for sustained-release intravitreal implant
Author(s)OT Staff Reports
Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.
Advertisement
Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
Aviceda Therapeutics reports positive phase 2b SIGLEC results for AVD-104 in geographic atrophy
2
Timely interventions can protect vision in patients with GA
3
Monitoring MacTel: Why BCVA does not tell the whole story
4
Enhancing Durability and Fluid Control with Aflibercept 8 mg in Retinal Vascular Diseases
5










































